Welcome to our dedicated page for Dbv Technologies SEC filings (Ticker: DBVTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A.'s SEC filings document a foreign issuer reporting framework for ordinary shares and American Depositary Shares. Form 8-K reports furnish financial results and business highlights, disclose registered securities, and record material governance and compensation actions.
Proxy materials for DBV Technologies S.A. cover shareholder voting matters, board authorization, compensation committee recommendations and equity award authority under French corporate law. The filings also identify ADS terms in which each American Depositary Share represents five ordinary shares, with the ADSs registered on Nasdaq under DBVT.
DBV Technologies S.A. received an updated Schedule 13G/A from a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of December 31, 2025, they collectively reported beneficial ownership of 14,350,960 Ordinary Shares, equal to 6.2% of the company’s Ordinary Shares.
The position consists of Ordinary Shares and American Depositary Shares, with each ADS representing five Ordinary Shares. The filing attributes control of the various Invus and Avicenna entities up a chain to Raymond Debbane, who may be deemed to beneficially own the same 6.2% stake. The group certifies the holdings are not for the purpose of changing or influencing control of DBV Technologies.
DBV Technologies S.A. received an updated Schedule 13G/A from a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of December 31, 2025, they collectively reported beneficial ownership of 14,350,960 Ordinary Shares, equal to 6.2% of the company’s Ordinary Shares.
The position consists of Ordinary Shares and American Depositary Shares, with each ADS representing five Ordinary Shares. The filing attributes control of the various Invus and Avicenna entities up a chain to Raymond Debbane, who may be deemed to beneficially own the same 6.2% stake. The group certifies the holdings are not for the purpose of changing or influencing control of DBV Technologies.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. reported that Daniel Soland has resigned from its Board of Directors and from the Board’s compensation committee, effective September 18, 2025. The company states that his resignation was not due to any dispute or disagreement with the company or the Board, indicating an orderly departure rather than a conflict-driven exit.
DBV Technologies also issued a press release on September 18, 2025 to announce this Board change, which is included as an exhibit to this report for additional background on the transition.